340B Drug Pricing Program
This template provides hospitals with an easy way to share their mission and community served and the impact if the 340B program is scaled back.
To ensure good stewardship of the 340B program, hospitals participating in the program should structure hospital policies and practices to demonstrate their commitment. That demonstration of commitment includes sharing publicly how 340B savings are used to benefit the community, by, for example鈥
The AHA, Association of American Medical Colleges, America鈥檚 Essential Hospitals, 340B Health and three hospital systems today asked a federal court to order the Department of Health and Human Services to make effective within 30 days a final rule requiring drug companies to disclose the ceiling鈥
September 11, 2018: The AHA, Association of American Medical Colleges, America鈥檚 Essential Hospitals, 340B Health and three hospital systems today asked a federal court to order the Department of Health and Human Services to make effective within 30 days a final rule requiring drug companies to鈥
Rural AdvocacySenate Hearing Examines Rural Health Care: The Senate Finance Committee May 24 held a hearing on "Rural Health Care in America: Challenges and Opportunities." In a statement submitted for the record, AHA recommended legislative and regulatory actions to maintain access to health care鈥
The AHA, Association of American Medical Colleges, America鈥檚 Essential Hospitals, and three hospital plaintiffs today refiled a lawsuit in federal district court seeking expedited relief from Medicare payment cuts for many hospitals in the 340B Drug Pricing Program.
Complaint and brief: The 黑料正能量 Association (AHA), the Association of American Medical Colleges (AAMC), and America鈥檚 Essential Hospitals, along with three hospital plaintiffs, refiled their lawsuit against the HHS to reverse Medicare payment cuts for many hospitals in the 340B Drug鈥
A recent article in the New York Times, 鈥淎 Little-Known Windfall for Some Hospitals, Now Facing Big Cuts,鈥 gives a thoroughly inaccurate and misleading view of the 340B Drug Pricing Program.